Human skeletal myopathy myosin mutations disrupt myosin head sequestration.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
08 Nov 2023
Historique:
received: 15 05 2023
accepted: 20 09 2023
medline: 9 11 2023
pubmed: 3 10 2023
entrez: 3 10 2023
Statut: epublish

Résumé

Myosin heavy chains encoded by MYH7 and MYH2 are abundant in human skeletal muscle and important for muscle contraction. However, it is unclear how mutations in these genes disrupt myosin structure and function leading to skeletal muscle myopathies termed myosinopathies. Here, we used multiple approaches to analyze the effects of common MYH7 and MYH2 mutations in the light meromyosin (LMM) region of myosin. Analyses of expressed and purified MYH7 and MYH2 LMM mutant proteins combined with in silico modeling showed that myosin coiled coil structure and packing of filaments in vitro are commonly disrupted. Using muscle biopsies from patients and fluorescent ATP analog chase protocols to estimate the proportion of myosin heads that were super-relaxed, together with x-ray diffraction measurements to estimate myosin head order, we found that basal myosin ATP consumption was increased and the myosin super-relaxed state was decreased in vivo. In addition, myofiber mechanics experiments to investigate contractile function showed that myofiber contractility was not affected. These findings indicate that the structural remodeling associated with LMM mutations induces a pathogenic state in which formation of shutdown heads is impaired, thus increasing myosin head ATP demand in the filaments, rather than affecting contractility. These key findings will help design future therapies for myosinopathies.

Identifiants

pubmed: 37788100
pii: 172322
doi: 10.1172/jci.insight.172322
doi:
pii:

Substances chimiques

Myosins EC 3.6.4.1
Adenosine Triphosphate 8L70Q75FXE

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Glenn Carrington (G)

The Astbury Centre for Structural and Molecular Biology and.
School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.

Abbi Hau (A)

Centre of Human and Applied Physiological Sciences and.
Randall Centre for Cell and Molecular Biophysics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, United Kingdom.

Sarah Kosta (S)

Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.

Hannah F Dugdale (HF)

Centre of Human and Applied Physiological Sciences and.
School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, United Kingdom.

Francesco Muntoni (F)

UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
NIHR Biomedical Research Centre at Great Ormond Street Hospital, Great Ormond Street, London, United Kingdom.

Adele D'Amico (A)

Department of Neurosciences, Unit of Neuromuscular and Neurodegenerative Disorders, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.

Peter Van den Bergh (P)

Neuromuscular Reference Center, Neurology Department, University Hospital Saint-Luc, Brussels, Belgium.

Norma B Romero (NB)

Neuromuscular Morphology Unit, Institute of Myology, Myology Research Centre INSERM, Sorbonne University, Hôpital Pitié-Salpêtrière, Paris, France.

Edoardo Malfatti (E)

APHP, Centre de Référence de Pathologie Neuromusculaire Nord-Est-Ile-de-France, Henri Mondor Hospital, Inserm U955, Creteil, France.
U1179 UVSQ-INSERM Handicap Neuromuscular: Physiology, Biotherapy and Applied Pharmacology, UFR Simone Veil-Santé, Université Versailles Saint Quentin en Yvelines, Paris-Saclay, France.

Juan Jesus Vilchez (JJ)

Neuromuscular and Ataxias Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) Spain, Valencia, Spain.

Anders Oldfors (A)

Department of Laboratory Medicine, University of Gothenburg, Gothenburg, Sweden.

Sander Pajusalu (S)

Genetics and Personalized Medicine Clinic, Tartu University Hospital, Tartu, Estonia.
Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.

Katrin Õunap (K)

Genetics and Personalized Medicine Clinic, Tartu University Hospital, Tartu, Estonia.
Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.

Marta Giralt-Pujol (M)

The Astbury Centre for Structural and Molecular Biology and.
School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.

Edmar Zanoteli (E)

Universidade de São Paulo, Hospital das Clínicas, Faculty of Medicine, Department of Neurology, São Paulo SP, Brazil.
Universidade Federal de São Paulo, Escola Paulista de Medicina, Department of Neurology, São Paulo SP, Brazil.

Kenneth S Campbell (KS)

Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky, USA.

Hiroyuki Iwamoto (H)

SPring-8, Japan Synchrotron Radiation Research Institute, Hyogo, Japan.

Michelle Peckham (M)

The Astbury Centre for Structural and Molecular Biology and.
School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.

Julien Ochala (J)

Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH